Your browser is no longer supported. Please, upgrade your browser.
ATOS Atossa Therapeutics, Inc. monthly Stock Chart
Atossa Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.38 Insider Own0.50% Shs Outstand10.49M Perf Week14.29%
Market Cap16.68M Forward P/E- EPS next Y-1.33 Insider Trans0.00% Shs Float10.46M Perf Month13.55%
Income-13.00M PEG- EPS next Q-0.45 Inst Own6.90% Short Float2.78% Perf Quarter-30.98%
Sales- P/S- EPS this Y63.10% Inst Trans177.03% Short Ratio1.29 Perf Half Y-30.16%
Book/sh0.91 P/B1.93 EPS next Y14.30% ROA-108.10% Target Price- Perf Year29.41%
Cash/sh0.96 P/C1.83 EPS next 5Y- ROE-130.60% 52W Range0.75 - 5.08 Perf YTD12.10%
Dividend- P/FCF- EPS past 5Y53.30% ROI- 52W High-65.35% Beta2.42
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low133.11% ATR0.12
Employees2 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)55.44 Volatility8.92% 8.29%
OptionableYes Debt/Eq0.00 EPS Q/Q4.60% Profit Margin- Rel Volume1.55 Prev Close1.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume225.22K Price1.76
Recom2.00 SMA2016.17% SMA50-7.65% SMA200-24.02% Volume348,324 Change1.15%
Jan-26-18Initiated Maxim Group Buy $2
Nov-17-20 08:00AM  
Nov-13-20 09:30AM  
Nov-10-20 09:30AM  
Oct-28-20 07:03AM  
Oct-19-20 09:30AM  
Oct-07-20 09:30AM  
Oct-02-20 09:20AM  
Sep-21-20 06:09PM  
Sep-17-20 09:30AM  
Sep-14-20 08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 09:30AM  
Aug-31-20 06:12PM  
Aug-26-20 09:30AM  
Aug-17-20 09:30AM  
Aug-13-20 09:30AM  
Aug-05-20 11:04AM  
Aug-03-20 09:30AM  
Jul-30-20 09:30AM  
Jul-27-20 09:30AM  
Jul-21-20 10:12PM  
Jul-16-20 09:15AM  
Jul-15-20 09:30AM  
Jul-08-20 09:30AM  
Jun-13-20 08:05AM  
Jun-11-20 09:30AM  
Jun-05-20 03:49PM  
May-29-20 08:00AM  
May-28-20 09:30AM  
May-20-20 09:30AM  
May-13-20 09:30AM  
May-07-20 09:30AM  
Apr-27-20 08:00AM  
Apr-22-20 03:40PM  
Apr-20-20 08:00AM  
Apr-17-20 10:51AM  
Apr-16-20 08:00AM  
Apr-02-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:30AM  
Mar-02-20 08:30AM  
Feb-05-20 08:00AM  
Feb-04-20 05:10PM  
Jan-22-20 08:30AM  
Jan-06-20 08:00AM  
Dec-19-19 08:30AM  
Dec-16-19 11:09AM  
Dec-05-19 08:30AM  
Nov-13-19 08:00AM  
Oct-23-19 08:30AM  
Oct-16-19 08:30AM  
Oct-15-19 08:30AM  
Sep-30-19 08:30AM  
Sep-06-19 08:30AM  
Sep-03-19 08:00AM  
Aug-13-19 01:26PM  
Jul-30-19 08:30AM  
Jul-17-19 08:30AM  
Jul-11-19 08:30AM  
Jun-28-19 11:38AM  
Jun-27-19 08:00AM  
Jun-19-19 03:56PM  
May-30-19 08:00AM  
May-13-19 05:21PM  
Apr-30-19 06:10AM  
Apr-25-19 12:00PM  
Apr-22-19 08:45AM  
Mar-28-19 04:30PM  
Mar-27-19 10:15AM  
Mar-26-19 08:30AM  
Mar-18-19 08:30AM  
Mar-14-19 01:01PM  
Feb-27-19 06:05AM  
Feb-07-19 08:30AM  
Feb-04-19 08:30AM  
Jan-30-19 09:15AM  
Jan-28-19 08:00AM  
Jan-10-19 07:00AM  
Jan-09-19 11:58AM  
Dec-28-18 07:20AM  
Dec-19-18 08:05AM  
Dec-07-18 12:07PM  
Dec-03-18 08:00AM  
Nov-21-18 08:05AM  
Nov-13-18 04:10PM  
Oct-25-18 09:10AM  
Oct-18-18 04:00PM  
Oct-11-18 08:00AM  
Sep-26-18 09:05AM  
Sep-25-18 08:20AM  
Sep-14-18 09:10AM  
Sep-13-18 08:00AM  
Sep-12-18 08:00AM  
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.